Abstract:Background Lung cancer is the most prevalent and lethal cancer globally, necessitating accurate differentiation between benign and malignant pulmonary nodules to guide treatment decisions. This study aims to develop a predictive model that integrates artificial intelligence (AI) analysis with biomarkers to enhance early detection and stratification of lung nodule malignancy. Methods The study retrospectively analyzed the patients with pathologically confirmed pulmonary nodules. AI technology was employed to assess CT features, such as nodule size, solidity, and malignancy probability. Additionally, lung cancer blood biomarkers were measured. Statistical analysis involved univariate analysis to identify significant differences among factors, followed by multivariate logistic regression to establish independent risk factors. The model performance was validated using receiver operating characteristic curves and decision curve analysis (DCA) for internal validation. Furthermore, an external dataset comprising 51 cases of lung nodules was utilized for independent validation to assess robustness and generalizability. Results A total of 176 patients were included, divided into benign/preinvasive ( n = 76) and invasive cancer groups ( n = 100). Multivariate analysis identified eight independent predictors of malignancy: lobulation sign, bronchial inflation sign, AI-predicted malignancy probability, nodule nature, diameter, solidity proportion, vascular endothelial growth factor, and lung cancer autoantibodies. The combined predictive model demonstrated high accuracy (area under the curve [AUC] = 0.946). DCA showed that the combined model significantly outperformed the traditional model, and also proved superior to models using AI-predicted malignancy probability or the seven lung cancer autoantibodies plus traditional model. External validation confirmed its robustness (AUC = 0.856), achieving a sensitivity of 0.80 and specificity of 0.86, effectively distinguishing between invasive and noninvasive nodules. Conclusion This combined approach of AI-based CT features analysis with lung cancer biomarkers provides a more accurate and clinically useful tool for guiding treatment decisions in pulmonary nodule patients. Further studies with larger cohorts are warranted to validate these findings across diverse patient populations. Received: 07 May 2024 Accepted: 01 October 2024 Article published online: 26 November 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Total Nodule Number As an Independent Prognostic Factor in Resected Stage III Non-Small Cell Lung Cancer: a Deep Learning-Powered Study

Deep learning model based on primary tumor to predict lymph node status in clinical stage IA lung adenocarcinoma: a multicenter study

Predictive Risk Factors for Lymph Node Metastasis in Patients with Small Size Non-Small Cell Lung Cancer.

Deep learning-powered 3D segmentation derives factors associated with lymphovascular invasion and prognosis in clinical T1 stage non-small cell lung cancer

Role of Pathologic Single-N and Multiple-N Descriptors in Resected Non-Small Cell Lung Cancer

Artificial intelligence-based radiomics for the prediction of nodal metastasis in early-stage lung cancer

DeepLN: A Multi-Task AI Tool to Predict the Imaging Characteristics, Malignancy and Pathological Subtypes in CT-Detected Pulmonary Nodules

Number of involved nodal stations: a better lymph node classification for clinical stage IA lung adenocarcinoma

Artificial intelligence based on deep learning for differential diagnosis between benign and malignant pulmonary nodules: A real-world, multicenter, diagnostic study.

Which is the better prognostic factor for resected non-small cell lung cancer: the number of metastatic lymph nodes or the currently used nodal stage classification?

The Value of Pulmonary Nodule Diameter and Consolidation/tumor Rate in the Prediction of Lymph Node Metastasis in Early-Stage (ct1n0m0) Lung Adenocarcinoma.

The prognostic significance of lymph nodes in patients with pT1c33N0M0 non-small cell lung cancer: a retrospective study

Invasiveness assessment by artificial intelligence against intraoperative frozen section for pulmonary nodules ≤ 3 cm

Prognostic Value of Preoperative N Subcategories in Patients with Stage IIIA N2 Non-Small Cell Lung Cancer

A Predictive Model Integrating AI Recognition Technology and Biomarkers for Lung Nodule Assessment

Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients with Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer

Predicting Benign, Preinvasive, and Invasive Lung Nodules on Computed Tomography Scans Using Machine Learning

Combining Node Location and Node Ratio As a Prognostic Factor for Surgical Resected Non-Small Cell Lung Cancer: a Population-Based Study.

An artificial intelligence-assisted diagnostic system for the prediction of benignity and malignancy of pulmonary nodules and its practical value for patients with different clinical characteristics

Potential added value of an AI software with prediction of malignancy for the management of incidental lung nodules

Deep Learning for Prediction of N2 Metastasis and Survival for Clinical Stage I Non–Small Cell Lung Cancer